{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:32Z","timestamp":1792783352761,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Health Commission Research Center for Medical and Health Technology Development Research Project","award":["WKZX2024HK0101"],"award-info":[{"award-number":["WKZX2024HK0101"]}]},{"name":"National Health Commission Research Center for Medical and Health Technology Development Research Project","award":["WKZX2024HK0101"],"award-info":[{"award-number":["WKZX2024HK0101"]}]},{"name":"National Health Commission Research Center for Medical and Health Technology Development Research Project","award":["WKZX2024HK0101"],"award-info":[{"award-number":["WKZX2024HK0101"]}]},{"name":"Guangzhou Medical University Research Capacity Enhancement Program Major Clinical Research Project","award":["GMUCR2025-02015"],"award-info":[{"award-number":["GMUCR2025-02015"]}],"id":[{"id":"https:\/\/ror.org\/00zat6v61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangzhou Medical University Research Capacity Enhancement Program Major Clinical Research Project","award":["GMUCR2025-02015"],"award-info":[{"award-number":["GMUCR2025-02015"]}],"id":[{"id":"https:\/\/ror.org\/00zat6v61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangzhou Medical University Research Capacity Enhancement Program Major Clinical Research Project","award":["GMUCR2025-02015"],"award-info":[{"award-number":["GMUCR2025-02015"]}],"id":[{"id":"https:\/\/ror.org\/00zat6v61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Center for School Planning & Development, Ministry of Education\u2014Innovation Research Project on New-quality Productivity for Industry-Education Integration","award":["CSDP26LF8A412"],"award-info":[{"award-number":["CSDP26LF8A412"]}]},{"name":"Center for School Planning & Development, Ministry of Education\u2014Innovation Research Project on New-quality Productivity for Industry-Education Integration","award":["CSDP26LF8A412"],"award-info":[{"award-number":["CSDP26LF8A412"]}]},{"name":"Center for School Planning & Development, Ministry of Education\u2014Innovation Research Project on New-quality Productivity for Industry-Education Integration Number","award":["CSDP26LF8A412"],"award-info":[{"award-number":["CSDP26LF8A412"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01412-1","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:56:45Z","timestamp":1788512205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Anti-PD-1\/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"Mingtai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"1412_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","volume":"24","author":"Y Iwai","year":"2017","unstructured":"Iwai Y, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26.","journal-title":"J Biomed Sci"},{"issue":"7","key":"1412_CR2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, et al. PD-L1 Expression in Lung Cancer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2016;11(7):964\u201375.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"6","key":"1412_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417\u201327.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1412_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"issue":"12","key":"1412_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jcb.30344","volume":"123","author":"A Ahmad","year":"2022","unstructured":"Ahmad A, Nawaz MI. Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem. 2022;123(12):1938\u201365.","journal-title":"J Cell Biochem"},{"key":"1412_CR6","doi-asserted-by":"crossref","unstructured":"Ishikura N et al. Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1low and immune desert-like mouse tumors. Oncol Rep, 2021. 47(2).","DOI":"10.3892\/or.2021.8247"},{"key":"1412_CR7","doi-asserted-by":"crossref","unstructured":"Allen E et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med, 2017. 9(385).","DOI":"10.1126\/scitranslmed.aak9679"},{"issue":"11","key":"1412_CR8","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"4","key":"1412_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"2","key":"1412_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"11","key":"1412_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1412_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","volume":"152","author":"T Gu","year":"2023","unstructured":"Gu T, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer. 2023;152(3):480\u201395.","journal-title":"Int J Cancer"},{"issue":"19","key":"1412_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10183","key":"1412_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (London England). 2019;393(10183):1819\u201330.","journal-title":"Lancet (London England)"},{"issue":"14","key":"1412_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"6230","key":"1412_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Sci (New York N Y). 2015;348(6230):124\u20138.","journal-title":"Sci (New York N Y)"},{"issue":"25","key":"1412_CR17","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"issue":"7","key":"1412_CR18","doi-asserted-by":"publisher","first-page":"e10293","DOI":"10.15252\/emmm.201910293","volume":"11","author":"M Zuazo","year":"2019","unstructured":"Zuazo M, et al. Functional systemic CD4 immunity is required for clinical responses to PD-L1\/PD-1 blockade therapy. EMBO Mol Med. 2019;11(7):e10293.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1412_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.29271\/jcpsp.2025.03.341","volume":"35","author":"Q-M Zheng","year":"2025","unstructured":"Zheng Q-M, et al. Prognostic Significance of CD4\u2009+\u2009Tumour Infiltrating Lymphocytes in Patients with Non-Small Cell Lung Cancer Receiving PD-1\/PD-L1 Inhibitors Therapy. J Coll Physicians Surgeons\u2013Pakistan: JCPSP. 2025;35(3):341\u201350.","journal-title":"J Coll Physicians Surgeons\u2013Pakistan: JCPSP"},{"issue":"5930","key":"1412_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Sci (New York N Y). 2009;324(5930):1029\u201333.","journal-title":"Sci (New York N Y)"},{"issue":"4","key":"1412_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11033-015-3858-x","volume":"42","author":"R Courtnay","year":"2015","unstructured":"Courtnay R, et al. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42(4):841\u201351.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"1412_CR22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","volume":"95","author":"P Vaupel","year":"2019","unstructured":"Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95(7):912\u20139.","journal-title":"Int J Radiat Biol"},{"key":"1412_CR23","doi-asserted-by":"crossref","unstructured":"Faubert B et al. Lactate Metabolism in Human Lung Tumors. Cell, 2017. 171(2).","DOI":"10.1016\/j.cell.2017.09.019"},{"issue":"8","key":"1412_CR24","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/0008-5472.CAN-18-1604","volume":"79","author":"N Rohani","year":"2019","unstructured":"Rohani N, et al. Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes. Cancer Res. 2019;79(8):1952\u201366.","journal-title":"Cancer Res"},{"issue":"1","key":"1412_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf P, et al. Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol Cancer. 2023;22(1):207.","journal-title":"Mol Cancer"},{"issue":"5","key":"1412_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabol. 2016;24(5):657\u201371.","journal-title":"Cell Metabol"},{"issue":"7","key":"1412_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10585-012-9500-6","volume":"29","author":"JA Nagy","year":"2012","unstructured":"Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis. 2012;29(7):657\u201362.","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"1412_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/jcmm.12496","volume":"19","author":"L Qiao","year":"2015","unstructured":"Qiao L, et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med. 2015;19(2):315\u201326.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1412_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","volume":"20","author":"W Li","year":"2024","unstructured":"Li W, et al. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. Autophagy. 2024;20(1):114\u201330.","journal-title":"Autophagy"},{"issue":"1","key":"1412_CR30","doi-asserted-by":"publisher","first-page":"16468","DOI":"10.1038\/s41598-023-43122-w","volume":"13","author":"D Ye","year":"2023","unstructured":"Ye D, et al. High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC. Sci Rep. 2023;13(1):16468.","journal-title":"Sci Rep"},{"issue":"1","key":"1412_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41416-024-02892-4","volume":"132","author":"S Poghosyan","year":"2024","unstructured":"Poghosyan S, et al. VEGF-C propagates \u2018onward\u2019 colorectal cancer metastasis from liver to lung. Br J Cancer. 2024;132(1):69\u201380.","journal-title":"Br J Cancer"},{"key":"1412_CR32","doi-asserted-by":"crossref","unstructured":"Song C-Y et al. Visfatin Facilitates VEGF-D-Induced Lymphangiogenesis through Activating HIF-1\u03b1 and Suppressing miR-2277-3p in Human Chondrosarcoma. Int J Mol Sci, 2024. 25(10).","DOI":"10.3390\/ijms25105142"},{"key":"1412_CR33","doi-asserted-by":"crossref","unstructured":"Yang W et al. VEGFD\/VEGFR2 axis induces the dedifferentiation of high endothelial venules and impairs lymphocyte homing. JCI Insight, 2025. 10(14).","DOI":"10.1172\/jci.insight.191041"},{"issue":"7","key":"1412_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1412_CR35","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin M, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Investig. 2016;126(11):4157\u201373.","journal-title":"J Clin Investig"},{"issue":"2","key":"1412_CR36","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/jcmm.14027","volume":"23","author":"Y-S Lai","year":"2019","unstructured":"Lai Y-S, et al. Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells. J Cell Mol Med. 2019;23(2):1257\u201367.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"1412_CR37","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.7150\/ijbs.91492","volume":"20","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Histone lactylation: from tumor lactate metabolism to epigenetic regulation. Int J Biol Sci. 2024;20(5):1833\u201354.","journal-title":"Int J Biol Sci"},{"key":"1412_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Experimental Clin Cancer Research: CR. 2015;34:111.","journal-title":"J Experimental Clin Cancer Research: CR"},{"issue":"6","key":"1412_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"7","key":"1412_CR40","doi-asserted-by":"publisher","first-page":"e1002202","DOI":"10.1371\/journal.pbio.1002202","volume":"13","author":"R Haas","year":"2015","unstructured":"Haas R, et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLoS Biol. 2015;13(7):e1002202.","journal-title":"PLoS Biol"},{"issue":"6","key":"1412_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41422-020-0324-7","volume":"30","author":"N Ohkura","year":"2020","unstructured":"Ohkura N, Sakaguchi S. Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res. 2020;30(6):465\u201374.","journal-title":"Cell Res"},{"issue":"4","key":"1412_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas F, et al. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017;46(4):577\u201386.","journal-title":"Immunity"},{"key":"1412_CR43","doi-asserted-by":"crossref","unstructured":"Benmebarek M-R et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity, 2025. 58(4).","DOI":"10.1016\/j.immuni.2025.02.017"},{"issue":"9944","key":"1412_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet (London England). 2014;384(9944):665\u201373.","journal-title":"Lancet (London England)"},{"issue":"24","key":"1412_CR45","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542\u201350.","journal-title":"N Engl J Med"},{"issue":"2","key":"1412_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143\u201355.","journal-title":"Lancet Oncol"},{"issue":"29","key":"1412_CR47","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1200\/JCO.2012.42.6932","volume":"30","author":"R Ramlau","year":"2012","unstructured":"Ramlau R, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2012;30(29):3640\u20137.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"21","key":"1412_CR48","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, et al. phase 2 Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40(21):2295\u2013306.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"9","key":"1412_CR49","doi-asserted-by":"publisher","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, et al. NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 7.2025. J Natl Compr Cancer Network: JNCCN. 2025;23(9):354\u201362.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"11","key":"1412_CR50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","volume":"36","author":"A Zer","year":"2025","unstructured":"Zer A, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol. 2025;36(11):1245\u201362.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"2","key":"1412_CR51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.20892\/j.issn.2095-3941.2024.0200","volume":"22","author":"J Wang","year":"2025","unstructured":"Wang J, Qiu T, Ren S. Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines. Cancer Biology Med. 2025;22(2):77\u201382.","journal-title":"Cancer Biology Med"},{"issue":"7","key":"1412_CR52","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41591-025-03658-y","volume":"31","author":"C Zhou","year":"2025","unstructured":"Zhou C, et al. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025;31(7):2375\u201384.","journal-title":"Nat Med"},{"issue":"23","key":"1412_CR53","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, et al. Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2013;31(23):2895\u2013902.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"22","key":"1412_CR54","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"key":"1412_CR55","unstructured":"Li X, et al. Updated results of BRAIN-AF01: adebrelimab combined with famitinib\/bevacizumab in PD-L1\u2009\u2265\u200950% advanced NSCLC with brain metastases. in. ESMO congress 2025. European Society for Medical Oncology; 2025."},{"issue":"9","key":"1412_CR56","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41416-023-02437-1","volume":"129","author":"P Brest","year":"2023","unstructured":"Brest P, et al. Checkpoint inhibitors and anti-angiogenic agents: a winning combination. Br J Cancer. 2023;129(9):1367\u201372.","journal-title":"Br J Cancer"},{"issue":"24","key":"1412_CR57","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"4","key":"1412_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1412_CR59","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.1038\/s41598-020-61840-3","volume":"10","author":"R Asano","year":"2020","unstructured":"Asano R, et al. Build-up functionalization of anti-EGFR \u00d7 anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats. Sci Rep. 2020;10(1):4913.","journal-title":"Sci Rep"},{"issue":"6","key":"1412_CR60","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/2211-5463.12073","volume":"6","author":"R Asano","year":"2016","unstructured":"Asano R, et al. Anti-EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half-life. FEBS Open Bio. 2016;6(6):594\u2013602.","journal-title":"FEBS Open Bio"},{"issue":"12 Suppl","key":"1412_CR61","doi-asserted-by":"publisher","first-page":"B123","DOI":"10.1158\/1535-7163.TARG-23-B123","volume":"22","author":"T Zhong","year":"2023","unstructured":"Zhong T, et al. Abstract B123: Mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects. Mol Cancer Ther. 2023;22(12 Suppl):B123.","journal-title":"Mol Cancer Ther"},{"issue":"10481","key":"1412_CR62","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet (London England). 2025;405(10481):839\u201349.","journal-title":"Lancet (London England)"},{"issue":"10515","key":"1412_CR63","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","volume":"406","author":"Z Chen","year":"2025","unstructured":"Chen Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet (London England). 2025;406(10515):2078\u201388.","journal-title":"Lancet (London England)"},{"issue":"10548","key":"1412_CR64","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/S0140-6736(26)00966-9","volume":"407","author":"S Lu","year":"2026","unstructured":"Lu S, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet (London England). 2026;407(10548):2620\u20139.","journal-title":"Lancet (London England)"},{"key":"1412_CR65","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62:102106.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"1412_CR66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang W, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024;332(7):561\u201370.","journal-title":"JAMA"},{"issue":"3","key":"1412_CR67","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","volume":"19","author":"L Wang","year":"2023","unstructured":"Wang L, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2023;19(3):465\u201375.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"1","key":"1412_CR68","first-page":"e77381","volume":"17","author":"A Al Matairi","year":"2025","unstructured":"Al Matairi A, et al. Efficacy and Safety of Ivonescimab in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): A Systematic Review. Cureus. 2025;17(1):e77381.","journal-title":"Cureus"},{"issue":"3","key":"1412_CR69","first-page":"189","volume":"8","author":"C Wang","year":"2025","unstructured":"Wang C, et al. A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy. Antib Ther. 2025;8(3):189\u201396.","journal-title":"Antib Ther"},{"issue":"16 Suppl","key":"1412_CR70","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1200\/JCO.2025.43.16_suppl.8543","volume":"43","author":"L Wu","year":"2025","unstructured":"Wu L, et al. A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC. J Clin Oncol. 2025;43(16 Suppl):8543.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"1412_CR71","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1200\/JCO.2026.44.16_suppl.8513","volume":"44","author":"S Peters","year":"2026","unstructured":"Peters S, et al. Phase 2 data from ROSETTA Lung-02, a global randomized phase 2\/3 trial of pumitamig (PD-L1 \u00d7 VEGF-A bsAb) + chemotherapy in 1L NSCLC. J Clin Oncol. 2026;44(16 Suppl):8513.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1412_CR72","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","volume":"32","author":"S Sugawara","year":"2021","unstructured":"Sugawara S, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32(9):1137\u201347.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"9","key":"1412_CR73","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2025.05.016","volume":"20","author":"RS Herbst","year":"2025","unstructured":"Herbst RS, et al. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2025;20(9):1302\u201314.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"6","key":"1412_CR74","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2023.12.023","volume":"19","author":"JC-H Yang","year":"2024","unstructured":"Yang JC-H, et al. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2024;19(6):941\u201353.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"10","key":"1412_CR75","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jtho.2025.05.020","volume":"20","author":"NB Leighl","year":"2025","unstructured":"Leighl NB, et al. LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2025;20(10):1489\u2013504.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"20","key":"1412_CR76","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1200\/JCO.23.02166","volume":"42","author":"J Neal","year":"2024","unstructured":"Neal J, et al. CONTACT-01: A Randomized phase 3 Trial of Atezolizumab\u2009+\u2009Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncology: Official J Am Soc Clin Oncol. 2024;42(20):2393\u2013403.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"1412_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","volume":"35","author":"H Borghaei","year":"2023","unstructured":"Borghaei H, et al. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2023;35(1):66\u201376.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"9","key":"1412_CR78","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu S, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(9):1167\u201379.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1412_CR79","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2023","unstructured":"Park S, et al. phase 3, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncology: Official J Am Soc Clin Oncol. 2023;42(11):1241\u201351.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"4","key":"1412_CR80","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cac2.12654","volume":"45","author":"T Chu","year":"2025","unstructured":"Chu T, et al. Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial. Cancer Commun (London England). 2025;45(4):442\u201355.","journal-title":"Cancer Commun (London England)"},{"issue":"4","key":"1412_CR81","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, et al. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(4):643\u201352.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"1412_CR82","doi-asserted-by":"crossref","unstructured":"Ren S, et al. Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. Volume 3. JTO Clinical and Research Reports; 2022. p. 100312. 5.","DOI":"10.1016\/j.jtocrr.2022.100312"},{"issue":"6","key":"1412_CR83","doi-asserted-by":"publisher","first-page":"964","DOI":"10.21037\/tlcr-22-22","volume":"11","author":"G Gao","year":"2022","unstructured":"Gao G, et al. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. Translational Lung Cancer Res. 2022;11(6):964\u201374.","journal-title":"Translational Lung Cancer Res"},{"issue":"5","key":"1412_CR84","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","volume":"27","author":"C Zhou","year":"2020","unstructured":"Zhou C, et al. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. Clin Cancer Research: Official J Am Association Cancer Res. 2020;27(5):1296\u2013304.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"1412_CR85","doi-asserted-by":"crossref","unstructured":"Zhao J et al. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. J Immunother Cancer, 2023. 11(2).","DOI":"10.1136\/jitc-2022-006055"},{"key":"1412_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2022.09.011","volume":"173","author":"BH Herzog","year":"2022","unstructured":"Herzog BH, et al. Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. Lung Cancer (Amsterdam Netherlands). 2022;173:101\u20136.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"1412_CR87","doi-asserted-by":"crossref","unstructured":"Buja A et al. Patterns of Comorbidities in Lung Cancer Patients and Survival. Cancers, 2025. 17(9).","DOI":"10.3390\/cancers17091577"},{"issue":"1","key":"1412_CR88","first-page":"467","volume":"35","author":"Y Takayama","year":"2021","unstructured":"Takayama Y, et al. Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors. In vivo (Athens Greece). 2021;35(1):467\u201374.","journal-title":"In vivo (Athens Greece)"},{"issue":"1","key":"1412_CR89","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/15412555.2022.2058924","volume":"19","author":"C Rui","year":"2022","unstructured":"Rui C, et al. Cigarette Smoke or Motor Vehicle Exhaust Exposure Induces PD-L1 Upregulation in Lung Epithelial Cells in COPD Model Rats. COPD. 2022;19(1):206\u201315.","journal-title":"COPD"},{"issue":"6","key":"1412_CR90","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1164\/rccm.201504-0782OC","volume":"193","author":"RT McKendry","year":"2016","unstructured":"McKendry RT, et al. Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis. Am J Respir Crit Care Med. 2016;193(6):642\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"1412_CR91","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","volume":"32","author":"D Lee","year":"2024","unstructured":"Lee D, et al. PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders. Mol Therapy: J Am Soc Gene Therapy. 2024;32(12):4235\u201355.","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"5","key":"1412_CR92","doi-asserted-by":"publisher","first-page":"L958","DOI":"10.1152\/ajplung.00121.2020","volume":"320","author":"F Ritzmann","year":"2021","unstructured":"Ritzmann F, et al. Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD. Am J Physiol Lung Cell Mol Physiol. 2021;320(5):L958\u201368.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1412_CR93","doi-asserted-by":"publisher","first-page":"41202","DOI":"10.1038\/srep41202","volume":"7","author":"L Wang","year":"2017","unstructured":"Wang L, et al. The Role of Vascular Endothelial Growth Factor in Small-airway Remodelling in a Rat Model of Chronic Obstructive Pulmonary Disease. Sci Rep. 2017;7:41202.","journal-title":"Sci Rep"},{"key":"1412_CR94","doi-asserted-by":"crossref","unstructured":"Poto R et al. Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions. Cells, 2022. 11(10).","DOI":"10.3390\/cells11101720"},{"issue":"1","key":"1412_CR95","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/resp.13142","volume":"23","author":"G Westergren-Thorsson","year":"2018","unstructured":"Westergren-Thorsson G, et al. VEGF synthesis is induced by prostacyclin and TGF-\u03b2 in distal lung fibroblasts from COPD patients and control subjects: Implications for pulmonary vascular remodelling. Respirol (Carlton Vic). 2018;23(1):68\u201375.","journal-title":"Respirol (Carlton Vic)"},{"issue":"5","key":"1412_CR96","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.7150\/ijbs.103458","volume":"21","author":"X Li","year":"2025","unstructured":"Li X, et al. Neutrophils in tumor- and inflammation-induced lymphangiogenesis. Int J Biol Sci. 2025;21(5):2223\u201334.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"1412_CR97","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.21037\/tlcr-22-667","volume":"11","author":"K Zhang","year":"2022","unstructured":"Zhang K, et al. Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study. Translational Lung Cancer Res. 2022;11(11):2306\u201317.","journal-title":"Translational Lung Cancer Res"},{"issue":"699","key":"1412_CR98","doi-asserted-by":"publisher","first-page":"eadh8005","DOI":"10.1126\/scitranslmed.adh8005","volume":"15","author":"BH Herzog","year":"2023","unstructured":"Herzog BH, et al. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci Transl Med. 2023;15(699):eadh8005.","journal-title":"Sci Transl Med"},{"issue":"22","key":"1412_CR99","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"5","key":"1412_CR100","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs. 2021;81(5):575\u201386.","journal-title":"Drugs"},{"key":"1412_CR101","doi-asserted-by":"crossref","unstructured":"Duitman J, van den Ende T, Spek CA. Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis? J Clin Med, 2019. 8(10).","DOI":"10.3390\/jcm8101547"},{"key":"1412_CR102","doi-asserted-by":"crossref","unstructured":"Chen S, et al. Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma. Volume 80. Pulmonary Pharmacology & Therapeutics; 2023. p. 102202.","DOI":"10.1016\/j.pupt.2023.102202"},{"key":"1412_CR103","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2020.12.016","volume":"145","author":"B Duchemann","year":"2021","unstructured":"Duchemann B, et al. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer (Oxford England: 1990). 2021;145:179\u201382.","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"issue":"12","key":"1412_CR104","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","volume":"15","author":"S Ikeda","year":"2020","unstructured":"Ikeda S, et al. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2020;15(12):1935\u201342.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"7","key":"1412_CR105","first-page":"609","volume":"48","author":"\u4e2d\u534e\u533b\u5b66\u4f1a\u547c\u5438\u75c5\u5b66\u5206\u4f1a","year":"2025","unstructured":"\u4e2d\u534e\u533b\u5b66\u4f1a\u547c\u5438\u75c5\u5b66\u5206\u4f1a. \u80ba\u764c\u5408\u5e76\u95f4\u8d28\u6027\u80ba\u75be\u75c5\u8bca\u7597\u4e13\u5bb6\u5171\u8bc6. \u4e2d\u534e\u7ed3\u6838\u548c\u547c\u5438\u6742\u5fd7. 2025;48(7):609\u201322.","journal-title":"\u4e2d\u534e\u7ed3\u6838\u548c\u547c\u5438\u6742\u5fd7"},{"issue":"4","key":"1412_CR106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5551\/jat.64183","volume":"31","author":"S Miyazaki","year":"2023","unstructured":"Miyazaki S, et al. Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease. J Atheroscler Thromb. 2023;31(4):355\u201367.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"1412_CR107","doi-asserted-by":"publisher","first-page":"e015761","DOI":"10.1161\/JAHA.119.015761","volume":"9","author":"H Wada","year":"2020","unstructured":"Wada H, et al. Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. J Am Heart Association. 2020;9(9):e015761.","journal-title":"J Am Heart Association"},{"issue":"5","key":"1412_CR108","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13543784.2025.2510666","volume":"34","author":"RR Guddeti","year":"2025","unstructured":"Guddeti RR, et al. A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development. Expert Opin Investig Drugs. 2025;34(5):363\u201370.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1412_CR109","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3892\/ol.2024.14648","volume":"28","author":"H Qian","year":"2024","unstructured":"Qian H, Li S, Hu Z. Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta-analysis. Oncol Lett. 2024;28(5):514.","journal-title":"Oncol Lett"},{"issue":"1","key":"1412_CR110","doi-asserted-by":"publisher","first-page":"114027","DOI":"10.1016\/j.yexcr.2024.114027","volume":"438","author":"H Jiang","year":"2024","unstructured":"Jiang H, Wu J, Zhang J. PD-1 and LAG-3 positive T cells are related with the prognosis of patients with chronic kidney disease. Exp Cell Res. 2024;438(1):114027.","journal-title":"Exp Cell Res"},{"key":"1412_CR111","doi-asserted-by":"publisher","first-page":"1530804","DOI":"10.3389\/fmed.2025.1530804","volume":"12","author":"A Hayashi","year":"2025","unstructured":"Hayashi A, et al. Increased serum soluble PD-L1 levels in patients with advanced stages of chronic kidney disease. Front Med. 2025;12:1530804.","journal-title":"Front Med"},{"issue":"4","key":"1412_CR112","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1161\/CIRCRESAHA.122.321939","volume":"132","author":"T Koide","year":"2023","unstructured":"Koide T, et al. Circulating Extracellular Vesicle-Propagated microRNA Signature as a Vascular Calcification Factor in Chronic Kidney Disease. Circul Res. 2023;132(4):415\u201331.","journal-title":"Circul Res"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01412-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:02:58Z","timestamp":1789639378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01412-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01412-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the article note was missing and should have read 'Mingtai Li and Zhiqing Wu are co-first authors'.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"45"}}